Alberto Malesci

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11524719/publications.pdf

Version: 2024-02-01

80	7,424	81839 39	64755 79
papers	citations	h-index	g-index

82	82	82	13067
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tumorâ€associated macrophages and risk of recurrence in stage <scp>III</scp> colorectal cancer. Journal of Pathology: Clinical Research, 2022, 8, 307-312.	1.3	5
2	Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes. International Journal of Molecular Sciences, 2021, 22, 5246.	1.8	9
3	Epithelial to Mesenchymal Transition: A Challenging Playground for Translational Research. Current Models and Focus on TWIST1 Relevance and Gastrointestinal Cancers. International Journal of Molecular Sciences, 2021, 22, 11469.	1.8	9
4	Prognostic and Predictive Cross-Roads of Microsatellite Instability and Immune Response to Colon Cancer. International Journal of Molecular Sciences, 2020, 21, 9680.	1.8	17
5	Iron Metabolism in Cancer Progression. International Journal of Molecular Sciences, 2020, 21, 2257.	1.8	65
6	Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. Journal of Autoimmunity, 2020, 114, 102511.	3.0	72
7	COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. Clinical Gastroenterology and Hepatology, 2020, 18, 2366-2368.e3.	2.4	51
8	mTOR-Dependent Stimulation of IL20RA Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohnâ€™s Disease. Cells, 2019, 8, 924.	1.8	12
9	Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. Cancer Research, 2019, 79, 4196-4210.	0.4	53
10	Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11. International Journal of Cancer, 2019, 145, 1913-1920.	2.3	16
11	Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression. Cancer Immunology Research, 2019, 7, 751-758.	1.6	29
12	Evolving notions on immune response in colorectal cancer and their implications for biomarker development. Inflammation Research, 2018, 67, 375-389.	1.6	32
13	Tumour-associated macrophages as treatment targets in oncology. Nature Reviews Clinical Oncology, 2017, 14, 399-416.	12.5	2,667
14	Hereditary or sporadic polyposis syndromes. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 409-417.	1.0	15
15	Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. OncoImmunology, 2017, 6, e1342918.	2.1	90
16	MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces ColitisÂinÂMice. Gastroenterology, 2017, 153, 1363-1377.e6.	0.6	48
17	Occurrence and significance of tumorâ€associated neutrophils in patients with colorectal cancer. International Journal of Cancer, 2016, 139, 446-456.	2.3	141
18	Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization. Inflammatory Bowel Diseases, 2016, 22, 2390-2401.	0.9	14

#	Article	IF	Citations
19	KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Medicine, 2016, 5, 256-264.	1.3	29
20	Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials. World Journal of Gastroenterology, 2016, 22, 4594.	1.4	42
21	The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation. Gut, 2015, 64, 589-600.	6.1	39
22	Bowel Damage as Assessed by the LÃ©mann Index is Reversible on Anti-TNF Therapy for Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2015, 9, 633-639.	0.6	65
23	Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers. Clinical Cancer Research, 2014, 20, 2147-2158.	3.2	264
24	A case of esophageal squamous cell intraepithelial neoplasia with positivity for type 16 human papillomavirus successfully treated with radiofrequency ablation. Journal of Gastrointestinal Oncology, 2014, 5, E36-9.	0.6	5
25	Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. Cancer, 2013, 119, 266-276.	2.0	34
26	Presence of Twist1-Positive Neoplastic Cells in the Stroma ofÂChromosome-Unstable Colorectal Tumors. Gastroenterology, 2013, 145, 647-657.e15.	0.6	49
27	High efficacy of endoscopic submucosal dissection for rectal laterally spreading tumors larger than 3 cm. Gastrointestinal Endoscopy, 2013, 77, 96-101.	0.5	80
28	Endoscopic submucosal dissection of early gastric neoplastic lesions. European Journal of Gastroenterology and Hepatology, 2013, 25, 1261-1264.	0.8	30
29	Prognostic value of innate and adaptive immunity in colorectal cancer. World Journal of Gastroenterology, 2013, 19, 174.	1.4	57
30	MSH3 Protein Expression and Nodal Status in MLH1-Deficient Colorectal Cancers. Clinical Cancer Research, 2012, 18, 3142-3153.	3.2	21
31	Microsatellite Instability and Therapeutic Consequences in Colorectal Cancer. Digestive Diseases, 2012, 30, 304-309.	0.8	39
32	Novel Prognostic Biomarkers in Colorectal Cancer. Digestive Diseases, 2012, 30, 296-303.	0.8	7
33	Irrelevance of Microsatellite Instability in the Epidemiology of Sporadic Pancreatic Ductal Adenocarcinoma. PLoS ONE, 2012, 7, e46002.	1.1	63
34	Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. Journal of Gastroenterology, 2012, 47, 159-168.	2.3	102
35	The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Digestive and Liver Disease, 2011, 43, 542-547.	0.4	140
36	Enhanced platelet adhesion induces angiogenesis in intestinal inflammation and inflammatory bowel disease microvasculature. Journal of Cellular and Molecular Medicine, 2011, 15, 625-634.	1.6	15

#	Article	IF	Citations
37	Nissen Fundoplication after Failure of Endoluminal Fundoplication: Short-Term Results. Journal of Gastrointestinal Surgery, 2011, 15, 439-443.	0.9	13
38	How dense, how intense? Role of tumourâ€infiltrating lymphocytes across colorectal cancer stages. Re: Nosho et al. Tumourâ€infiltrating Tâ€cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010; 222: 350â€“366. Journal of Pathology, 2011, 225, 628-628.	2.1	3
39	Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19830-19835.	3.3	63
40	Prognostic Value of Colorectal Cancer Biomarkers. Cancers, 2011, 3, 2080-2105.	1.7	5
41	Endoluminal Fundoplication (ELF) for GERD Using EsophyX: a 12-Month Follow-up in a Single-Center Experience. Journal of Gastrointestinal Surgery, 2010, 14, 1-6.	0.9	47
42	Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. Expert Review of Clinical Immunology, 2010, 6, 567-572.	1.3	37
43	Endoscopic submucosal dissection in patients with early esophageal squamous cell carcinoma: results from a prospective Western series. Gastrointestinal Endoscopy, 2010, 71, 715-721.	0.5	177
44	The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6. Gut, 2010, 59, 197-206.	6.1	138
45	Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?. Current Drug Targets, 2010, 11, 249-260.	1.0	24
46	Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: A pilot study. World Journal of Gastroenterology, 2010, 16, 2396.	1.4	48
47	Closure of perianal fistula using adalimumab in a CrohnÊ¼s disease patient naive to antitumor necrosis factor alpha antibodies. Inflammatory Bowel Diseases, 2009, 15, 814-815.	0.9	3
48	The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. European Journal of Immunology, 2009, 39, 290-300.	1.6	52
49	VEGF-A Links Angiogenesis and Inflammation in Inflammatory Bowel Disease Pathogenesis. Gastroenterology, 2009, 136, 585-595.e5.	0.6	289
50	CD3+ cells at the invasive margin of deeply invading (pT3â€“T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncology, The, 2009, 10, 877-884.	5.1	226
51	T1687 Infliximab Inhibits Mucosal Pathological Angiogenesis in Crohn's Disease. Gastroenterology, 2009, 136, A-558.	0.6	1
52	Endoscopic Mucosal Resection for Early Colorectal Neoplasia: Pathologic Basis, Procedures, and Outcomes. Diseases of the Colon and Rectum, 2009, 52, 1502-1515.	0.7	121
53	Biological agents for ulcerative colitis: Hypes and hopes. Medicinal Research Reviews, 2008, 28, 201-218.	5.0	24
54	Successful treatment of fistulizing CrohnÊ¼s disease with certolizumab pegol. Inflammatory Bowel Diseases, 2008, 14, 292-293.	0.9	9

#	Article	IF	Citations
55	Successful induction of clinical response and remission with certolizumab pegol in CrohnÊ¼s disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use. Inflammatory Bowel Diseases, 2008, 14, 1168-1170.	0.9	21
56	Anti-adhesion molecule therapies in inflammatory bowel disease: Touch and go. Autoimmunity Reviews, 2008, 7, 364-369.	2.5	42
57	Unique Role of Junctional Adhesion Molecule-A in Maintaining Mucosal Homeostasis in Inflammatory Bowel Disease. Gastroenterology, 2008, 135, 173-184.	0.6	210
58	Multiple Pathogenic Roles of Microvasculature in Inflammatory Bowel Disease: A Jack of All Trades. American Journal of Pathology, 2008, 172, 1457-1466.	1.9	125
59	Cytapheresis in Inflammatory Bowel Diseases: Current Evidence and Perspectives. Digestion, 2008, 77, 96-107.	1.2	13
60	Reply to the Letter to the Editor from Watanabe et al. Clinical Cancer Research, 2008, 14, 2516-2516.	3.2	0
61	Insulated-Tip Knife Endoscopic Mucosal Resection of Large Colorectal Polyps Unsuitable for Standard Polypectomy. American Journal of Gastroenterology, 2007, 102, 1617-1623.	0.2	40
62	Tumor Necrosis Factor-Alpha Monoclonal Antibodies for Crohns Disease: Tipping the Balance. Current Medicinal Chemistry, 2007, 14, 1489-1497.	1.2	11
63	Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer. Clinical Cancer Research, 2007, 13, 3831-3839.	3.2	221
64	Inflammation and Coagulation in Inflammatory Bowel Disease: The Clot Thickens. American Journal of Gastroenterology, 2007, 102, 174-186.	0.2	322
65	Laparoscopic Surgery in Rectal Cancer: A Prospective Analysis of Patient Survival and Outcomes. Diseases of the Colon and Rectum, 2007, 50, 2047-2053.	0.7	62
66	Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. Journal of Clinical Investigation, 2007, 117, 1951-1960.	3.9	105
67	Quantitative evaluation of RASSF1Amethylation in the non-lesional, regenerative and neoplastic liver. BMC Cancer, 2006, 6, 89.	1.1	56
68	Endoscopic Ultrasonography and Magnetic Resonance in Preoperative Staging of Rectal Cancer: Comparison With Histologic Findings. Journal of Gastrointestinal Surgery, 2005, 9, 1222-1228.	0.9	42
69	Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World Journal of Gastroenterology, 2005, 11, 7001.	1.4	49
70	Re: Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability. Journal of the National Cancer Institute, 2004, 96, 1402-1403.	3.0	30
71	Pancreatic cancer or chronic pancreatitis? An answer from PET/MRI image fusion. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1352.	3.3	13
72	Constraints imposed by supercoiling on in vitro amplification of polyomavirus DNA. Journal of General Virology, 2004, 85, 3383-3388.	1.3	7

#	Article	IF	Citations
73	Gender difference for promoter methylation pattern of hMLH1 and p16 in sporadic MSI colorectal cancer. Gastroenterology, 2003, 124, 1165-1166.	0.6	10
74	Frameshift Mutations of Human Gastrin Receptor Gene (hGARE) in Gastrointestinal Cancers with Microsatellite Instability. Laboratory Investigation, 2002, 82, 265-271.	1.7	21
75	Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology, 2002, 36, 427-432.	3.6	108
76	Clinical Utility of the Serum CA 19-9 Test for Diagnosing Pancreatic Carcinoma in Symptomatic Patients. Pancreas, 1992, 7, 497-502.	0.5	37
77	Pancreatic polypeptide secretion after insulin infusion and protein meal in juvenile type 1 diabetic subjects. Acta Diabetologica Latina, 1990, 27, 165-171.	0.2	4
78	Pancreatic Polypeptide Response to Food and Cerulein in Patients with Total Gastrectomy. Pancreas, 1989, 4, 538-542.	0.5	3
79	Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology, 1987, 92, 60-67.	0.6	99
80	Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer, 1987, 60, 2428-2431.	2.0	67